Wise Investments

[Scrooge McDuck]

XKEM news..............
NEW BRUNSWICK, N.J., Nov 17, 2003 (BUSINESS WIRE) --

Xechem International, Inc. (OTCBB: XKEM) today announced that it has received its first patent, #CA2210972, from the Canadian Patent and Trade Mark Office, on October 21, 2003, for its novel, efficient proprietary technology for Isolation and Purification of paclitaxel from Yew tree (Taxus brevifolia and Taxus species). This will protect Xechem's innovative technology which also leads to nine next generation paclitaxel analogs, till the year 2016. Xechem has several U.S. and international patents on its proprietary technology of this cancer drug. Paclitaxel was first approved by the FDA for ovarian cancer under the name of Taxol(R). Subsequently, Taxol was approved for breast cancer, small-cell lung and stomach cancers and AIDS related Kaposi Sarcoma. After becoming one of the largest selling cancer drugs in the world, it has subsequently become available as a generic. Xechem is pursuing a superior proprietary paclitaxel formulation.

'We are delighted to receive the Canadian patent, which protects our technology and further builds credibility for our proprietary paclitaxel,'said Dr. Ramesh C. Pandey, President and CEO of Xechem. 'We believe our formulation may be superior to the generic version.' Dr. Pandey added, 'As we commit our focus to orphan diseases with the development of drugs like HEMOXIN(TM) for Sickle Cell Disease (SCD), a proprietary paclitaxel for potential use in several cancers is a good strategic fit.'

Xechem International, Inc. is a fully integrated biopharmaceutical company focusing on proprietary products for orphan diseases.

This news release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks, uncertainties, including the ability of the Companies to successfully develop and commercialize their technologies, and other factors that may cause the actual results, performance or achievements of the Companies to be materially different from any future results, performance or achievements of the Companies expressed or implied by such forward-looking statements